{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:49:34Z","timestamp":1791409774477,"version":"4.3.3"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110301","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:17:56Z","timestamp":1785194276000},"page":"110301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From tumor imaging probes to boron neutron capture therapy: a strategy for designing targeted boron carriers for pancreatic Cancer"],"prefix":"10.1016","volume":"181","author":[{"given":"Li-Hong","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Lin","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Gui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Qi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Chen","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bioorg.2026.110301_bb0005","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1148\/rg.2020190184","article-title":"Pancreatic ductal adenocarcinoma and its variants: pearls and perils","volume":"40","author":"Schawkat","year":"2020","journal-title":"RadioGraphics"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110301_bb0010","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/MPA.0000000000001338","article-title":"Characteristics and outcomes of pancreatic Cancer by histological subtypes","volume":"48","author":"Luo","year":"2019","journal-title":"Pancreas"},{"issue":"15","key":"10.1016\/j.bioorg.2026.110301_bb0015","doi-asserted-by":"crossref","first-page":"7055","DOI":"10.3390\/ijms26157055","article-title":"Advances in the management of pancreatic Cancer: current strategies and emerging therapies","volume":"26","author":"Peshin","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110301_bb0020","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.110301_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ntm.2025.100081","article-title":"Boron delivery agents in BNCT: a mini review of current developments and emerging trends","volume":"4","author":"Murilla","year":"2025","journal-title":"Nano TransMed"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110301_bb0030","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.110301_bb0035","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1200\/EDBK_160827","article-title":"Localized pancreatic cancer: multidisciplinary management","volume":"36","author":"Coveler","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110301_bb0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41575-023-00856-2","article-title":"Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer","volume":"21","author":"Stoop","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3, Part 2","key":"10.1016\/j.bioorg.2026.110301_bb0045","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.lpm.2019.02.025","article-title":"Chemotherapy for pancreatic cancer","volume":"48","author":"Springfeld","year":"2019","journal-title":"Presse Med."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110301_bb0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00595-025-03109-8","article-title":"Adjuvant treatment after surgical resection of pancreatic cancer","volume":"56","author":"Tomimaru","year":"2026","journal-title":"Surg. Today"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110301_bb0055","first-page":"626","article-title":"Diagnosis and management of pancreatic cancer","volume":"89","author":"De La Cruz","year":"2014","journal-title":"Am. Fam. Physician"},{"issue":"19","key":"10.1016\/j.bioorg.2026.110301_bb0060","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3748\/wjg.v24.i19.2047","article-title":"Challenges in diagnosis of pancreatic cancer","volume":"24","author":"Zhang","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110301_bb0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000323479","article-title":"Biomarkers of pancreatic cancer","volume":"11","author":"Hamada","year":"2011","journal-title":"Pancreatology"},{"issue":"8_Supplement_1","key":"10.1016\/j.bioorg.2026.110301_bb0070","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1158\/1538-7445.AM2025-1371","article-title":"ChemoNETosis is associated with chemotherapy resistance in pancreatic cancer","volume":"85","author":"Nogi","year":"2025","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110301_bb0075","first-page":"64","article-title":"Clinical immunotherapy in pancreatic cancer, Cancer immunology","volume":"73","author":"Ye","year":"2024","journal-title":"Immunotherapy"},{"key":"10.1016\/j.bioorg.2026.110301_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216782","article-title":"Conquering chemoresistance in pancreatic cancer: exploring novel drug therapies and delivery approaches amidst desmoplasia and hypoxia","volume":"588","author":"Chintamaneni","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.110301_bb0085","series-title":"Boron reagents in synthesis","first-page":"1","article-title":"Boron chemistry: an overview","author":"DeFrancesco","year":"2016"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110301_bb0090","doi-asserted-by":"crossref","first-page":"324","DOI":"10.14219\/jada.archive.1938.0054","article-title":"Perborate as a bleaching agent","volume":"25","author":"Salvas","year":"1938","journal-title":"J. Am. Dent. Assoc. Dent. Cosmos"},{"issue":"21","key":"10.1016\/j.bioorg.2026.110301_bb0095","doi-asserted-by":"crossref","first-page":"14948","DOI":"10.1021\/acs.jmedchem.3c01516","article-title":"Structural patterns enhancing the antibacterial activity of metallacarborane-based antibiotics","volume":"66","author":"Cebula","year":"2023","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110301_bb0100","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3390\/molecules25040828","article-title":"Boron chemistry for medical applications","volume":"25","author":"Ali","year":"2020","journal-title":"Molecules"},{"issue":"3409","key":"10.1016\/j.bioorg.2026.110301_bb0105","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/135341a0","article-title":"Detection of nuclear disintegration in a photographic emulsion","volume":"135","author":"Taylor","year":"1935","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.bioorg.2026.110301_bb0110","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1021\/jm960787x","article-title":"Boron-containing polyamines as DNA targeting agents for neutron capture therapy of brain tumors: synthesis and biological evaluation","volume":"40","author":"Cai","year":"1997","journal-title":"J. Med. Chem."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2026.110301_bb0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF02699932","article-title":"A critical assessment of boron target compounds for boron neutron capture therapy","volume":"62","author":"Hawthorne","year":"2003","journal-title":"J. Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110301_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/3579742","article-title":"The radiation biology of boron neutron capture therapy","volume":"151","author":"Coderre","year":"1999","journal-title":"Radiat. Res."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110301_bb0125","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/cac2.12089","article-title":"Boron neutron capture therapy: current status and future perspectives","volume":"40","author":"Dymova","year":"2020","journal-title":"Cancer Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110301_bb0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10147-019-01480-4","article-title":"Boron neutron capture therapy (BNCT): a unique role in radiotherapy with a view to entering the accelerator-based BNCT era","volume":"25","author":"Suzuki","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110301_bb0135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110301_bb0140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1023\/A:1023220404800","article-title":"Fission reactor neutron sources for neutron capture therapy \u2014 a critical review","volume":"62","author":"Harling","year":"2003","journal-title":"J. Neuro-Oncol."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110301_bb0145","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1002\/onco.13805","article-title":"Designation products: boron neutron capture therapy for head and neck carcinoma","volume":"26","author":"Kanno","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2026.110301_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2019.213139","article-title":"Boron agents for neutron capture therapy","volume":"405","author":"Hu","year":"2020","journal-title":"Coord. Chem. Rev."},{"issue":"8659","key":"10.1016\/j.bioorg.2026.110301_bb0155","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0140-6736(89)90567-9","article-title":"Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound","volume":"334","author":"Mishima","year":"1989","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bioorg.2026.110301_bb0160","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.apradiso.2011.03.021","article-title":"Long-survivors of glioblatoma treated with boron neutron capture therapy (BNCT)","volume":"69","author":"Kageji","year":"2011","journal-title":"Appl. Radiat. Isot."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110301_bb0165","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.radonc.2011.02.008","article-title":"Boron neutron capture therapy (BNCT) followed by intensity modulated chemoradiotherapy as primary treatment of large head and neck cancer with intracranial involvement","volume":"99","author":"Kankaanranta","year":"2011","journal-title":"Radiother. Oncol."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110301_bb0170","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/cac2.12582","article-title":"Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT","volume":"44","author":"Barth","year":"2024","journal-title":"Cancer Commun."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110301_bb0175","article-title":"Boron neutron capture therapy as a novel approach for chondrosarcoma: case study of tumor reduction and long-term control","volume":"10","author":"Hong","year":"2025","journal-title":"Adv. Radiat. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.bioorg.2026.110301_bb0180","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1200\/JCO.2020.38.15_suppl.2536","article-title":"Accelerator-based BNCT in rescue treatment of patients with recurrent GBM: a multicenter phase II study","volume":"38","author":"Miyatake","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110301_bb0185","series-title":"Boron science: new technologies and applications, boron science: new technologies and applications","author":"Hosmane","year":"2016"},{"key":"10.1016\/j.bioorg.2026.110301_bb0190","article-title":"Advances in gadolinium-based composite materials for neutron and gamma-ray shielding","volume":"12\u20132025","author":"Chen","year":"2025","journal-title":"Front. Mater."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110301_bb0195","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/BF02349436","article-title":"On the effect of gadolinium in neutron capture therapy","volume":"240","author":"Alfassi","year":"1999","journal-title":"J. Radioanal. Nucl. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110301_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/inorganics7050059","article-title":"Potential of MRI in radiotherapy mediated by small conjugates and nanosystems","volume":"7","author":"Putri Fauzia","year":"2019","journal-title":"Inorganics"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110301_bb0205","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bmc.2004.10.046","article-title":"Synthesis and in vivo biodistribution of BPA\u2013Gd\u2013DTPA complex as a potential MRI contrast carrier for neutron capture therapy","volume":"13","author":"Takahashi","year":"2005","journal-title":"Bioorg. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110301_bb0210","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1021\/acscentsci.5c01632","article-title":"A comparative study of 157Gd and 10B effect in a carborane-based theranostic agent for membrane-targeted carbonic anhydrase IX inhibition and MRI-guided neutron capture therapy in mesothelioma treatment","volume":"11","author":"Rakhshan","year":"2025","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bioorg.2026.110301_bb0215","series-title":"Neutron capture therapy: principles and applications, neutron capture therapy: principles and applications","author":"Sauerwein","year":"2012"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110301_bb0220","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3390\/cells12101398","article-title":"Next-generation boron drugs and rational translational studies driving the revival of BNCT","volume":"12","author":"Seneviratne","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.110301_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2025.217555","article-title":"Achievements, challenges, and perspectives in the design of boron delivery agents for neutron capture therapy","volume":"553","author":"Yang","year":"2026","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.bioorg.2026.110301_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2024.215795","article-title":"Novel promising boron agents for boron neutron capture therapy: current status and outlook on the future","volume":"511","author":"Xu","year":"2024","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.bioorg.2026.110301_bb0235","article-title":"Advances in clinical trials of boron neutron capture therapy","volume":"9","author":"Li","year":"2026","journal-title":"Research"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110301_bb0240","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-0749.1989.tb00203.x","article-title":"Complex formation of p-boronophenylalanine with some monosaccharides","volume":"2","author":"Mori","year":"1989","journal-title":"Pigment Cell Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110301_bb0245","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00008390-199902000-00010","article-title":"Pharmacokinetics of 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients: a study of boron neutron capture therapy for malignant melanoma","volume":"9","author":"Fukuda","year":"1999","journal-title":"Melanoma Res."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110301_bb0250","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3390\/pharmaceutics14051106","article-title":"Evaluation of 3-Borono-l-phenylalanine as a water-soluble boron neutron capture therapy agent","volume":"14","author":"Kondo","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110301_bb0255","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00259-024-06600-5","article-title":"A bis-boron boramino acid PET tracer for brain tumor diagnosis","volume":"51","author":"Li","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110301_bb0260","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202413249","article-title":"A Bis-boron amino acid for positron emission tomography and boron neutron capture therapy","volume":"64","author":"Chen","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110301_bb0265","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1021\/acs.jmedchem.3c01835","article-title":"Peptide\u2013drug conjugates: an emerging direction for the next generation of peptide therapeutics","volume":"67","author":"Dean","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110301_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116119","article-title":"Peptide-drug conjugates: a new paradigm for targeted cancer therapy","volume":"265","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110301_bb0275","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/bjc.1991.124","article-title":"Application of boronated anti-CEA immunoliposome to tumour cell growth inhibition in in vitro boron neutron capture therapy model","volume":"63","author":"Yanagi\u00eb","year":"1991","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110301_bb0280","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/bjc.1997.118","article-title":"Inhibition of human pancreatic cancer growth in nude mice by boron neutron capture therapy","volume":"75","author":"Yanagi\u00eb","year":"1997","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110301_bb0285","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biopha.2005.05.011","article-title":"Application of boron-entrapped stealth liposomes to inhibition of growth of tumour cells in the in vivo boron neutron-capture therapy model","volume":"60","author":"Yanagie","year":"2006","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110301_bb0290","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz1722","article-title":"Poly(vinyl alcohol) boosting therapeutic potential of p-boronophenylalanine in neutron capture therapy by modulating metabolism","volume":"6","author":"Nomoto","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioorg.2026.110301_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122605","article-title":"BNCT pancreatic cancer treatment strategy with glucose-conjugated boron drug","volume":"309","author":"Fujimoto","year":"2024","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110301_bb0300","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1186\/s12967-025-07349-7","article-title":"Tumor marker\u2013guided precision BNCT for CA19-9\u2013positive cancers: a new paradigm in molecularly targeted chemoradiation therapy","volume":"23","author":"Kanehira","year":"2025","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110301_bb0305","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jphs.2019.01.012","article-title":"Boron delivery for boron neutron capture therapy targeting a cancer-upregulated oligopeptide transporter","volume":"139","author":"Miyabe","year":"2019","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2026.110301_bb0310","article-title":"Engineered \u03b1v\u03b26-targeting peptide\u2013BSH conjugates for boron neutron capture therapy of pancreatic ductal adenocarcinoma","author":"Li","year":"2026","journal-title":"Acta Pharm. Sin. B"},{"issue":"16","key":"10.1016\/j.bioorg.2026.110301_bb0315","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1158\/0008-5472.CAN-07-1026","article-title":"Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F] fluorobenzoyl A20FMDV2 for in vivo imaging of integrin \u03b1v\u03b26 expression with positron emission tomography","volume":"67","author":"Hausner","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110301_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113995","article-title":"Synthetic polypeptides for drug and gene delivery, and tissue engineering","volume":"178","author":"Yin","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2026.110301_bb0325","doi-asserted-by":"crossref","first-page":"10751","DOI":"10.2147\/IJN.S529323","article-title":"Recent progress in peptide-based fluorescent probes biomedical applications: a review","author":"Zhong","year":"2025","journal-title":"Int. J. Nanomedicine"},{"issue":"16","key":"10.1016\/j.bioorg.2026.110301_bb0330","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1039\/D3CS00056G","article-title":"Small-molecule probes from bench to bedside: advancing molecular analysis of drug\u2013target interactions toward precision medicine","volume":"52","author":"Pan","year":"2023","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioorg.2026.110301_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2025.117255","article-title":"Peptide-based fluorescent probes for the diagnosis of tumor and image-guided surgery","volume":"276","author":"Cai","year":"2025","journal-title":"Biosens. Bioelectron."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110301_bb0340","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2217\/14622416.9.5.597","article-title":"Pharmacogenetics of OATP (SLC21\/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney","volume":"9","author":"Za\u00efr","year":"2008","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110301_bb0345","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/med.22093","article-title":"Comparison of radionuclide drug conjugates with boron neutron capture therapy: an overview of targeted charged particle radiation therapy","volume":"45","author":"Zhang","year":"2025","journal-title":"Med. Res. Rev."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110301_bb0350","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110301_bb0355","first-page":"1469","article-title":"Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors","volume":"9","author":"Fj\u00e4llskog","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110301_bb0360","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3390\/cancers13112748","article-title":"EGFR in Cancer: signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers"},{"issue":"14","key":"10.1016\/j.bioorg.2026.110301_bb0365","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1096\/fj.05-4058com","article-title":"Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics","volume":"19","author":"Li","year":"2005","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110301_bb0370","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/pharmaceutics10010002","article-title":"GE11 peptide as an active targeting agent in antitumor therapy: a minireview","volume":"10","author":"Genta","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2026.110301_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2023.108364","article-title":"Integrin \u03b1v\u03b23 and EGFR dual-targeted [64Cu]Cu-NOTA-RGD-GE11 heterodimer for PET imaging in pancreatic cancer mouse model","volume":"124-125","author":"Li","year":"2023","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.bioorg.2026.110301_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.snb.2023.134102","article-title":"Near-infrared targeted EGFR fluorescent probe for tumor imaging and diagnosis","volume":"393","author":"Huang","year":"2023","journal-title":"Sens. Actuators B"},{"issue":"6120","key":"10.1016\/j.bioorg.2026.110301_bb0385","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/327339a0","article-title":"The solution structure of human epidermal growth factor","volume":"327","author":"Cooke","year":"1987","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110301_bb0390","doi-asserted-by":"crossref","first-page":"110992","DOI":"10.1016\/j.jbc.2025.110992","article-title":"EGFR-targeted gadolinium contrast agents for enhanced molecular magnetic resonance imaging of tumors","volume":"302","author":"Chen","year":"2025","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110301_bb0395","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","article-title":"The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer","volume":"35","author":"Hsu","year":"2016","journal-title":"Cancer Metastasis Rev."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110301_bb0400","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/gm482","article-title":"Clinical and molecular characterization of HER2amplified-pancreatic cancer","volume":"5","author":"Chou","year":"2013","journal-title":"Genome Med."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110301_bb0405","doi-asserted-by":"crossref","first-page":"8367","DOI":"10.1021\/acs.analchem.5b01588","article-title":"Microarray based screening of peptide nano probes for HER2 positive tumor","volume":"87","author":"Wang","year":"2015","journal-title":"Anal. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110301_bb0410","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.7150\/thno.14302","article-title":"HER2 targeting peptides screening and applications in tumor imaging and drug delivery","volume":"6","author":"Geng","year":"2016","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110301_bb0415","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cytogfr.2004.03.007","article-title":"The PDGF family: four gene products form five dimeric isoforms","volume":"15","author":"Fredriksson","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110301_bb0420","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF01646843","article-title":"Platelet-derived growth factor \u2014 a growth factor with an expanding role in health and disease","volume":"68","author":"Habenicht","year":"1990","journal-title":"Klin. Wochenschr."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110301_bb0425","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11307-012-0578-7","article-title":"Peptide-based targeting of the platelet-derived growth factor receptor beta","volume":"15","author":"Askoxylakis","year":"2013","journal-title":"Mol. Imaging Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110301_bb0430","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11307-013-0616-0","article-title":"Peptide arrays for development of PDGFR\u03b2 affine molecules","volume":"15","author":"Marr","year":"2013","journal-title":"Mol. Imaging Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110301_bb0435","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/molecules26010041","article-title":"Development of radiogallium-labeled peptides for platelet-derived growth factor receptor \u03b2 (PDGFR\u03b2) imaging: influence of different linkers","volume":"26","author":"Effendi","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110301_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2022.124225","article-title":"PDGFR\u03b2 targeted innovative imaging probe for pancreatic adenocarcinoma detection","volume":"255","author":"Gao","year":"2023","journal-title":"Talanta"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110301_bb0445","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/gb-2008-9-5-224","article-title":"Glypicans","volume":"9","author":"Filmus","year":"2008","journal-title":"Genome Biol."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110301_bb0450","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/PAP.0000000000000043","article-title":"Discovery and diagnostic value of a novel oncofetal protein: glypican 3","volume":"21","author":"Wang","year":"2014","journal-title":"Adv. Anat. Pathol."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110301_bb0455","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.3892\/mmr.2014.2600","article-title":"Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells","volume":"10","author":"Qi","year":"2014","journal-title":"Mol. Med. Rep."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110301_bb0460","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.humpath.2012.06.016","article-title":"Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms","volume":"44","author":"Mounajjed","year":"2013","journal-title":"Hum. Pathol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110301_bb0465","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3233\/CBM-160655","article-title":"Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma","volume":"17","author":"Yao","year":"2016","journal-title":"Cancer Biomark."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110301_bb0470","doi-asserted-by":"crossref","first-page":"1600335","DOI":"10.1002\/mabi.201600335","article-title":"Identification of a glypican-3-binding peptide for in vivo non-invasive human hepatocellular carcinoma detection","volume":"17","author":"Qin","year":"2017","journal-title":"Macromol. Biosci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110301_bb0475","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1039\/C8BM01016A","article-title":"An innovative peptide with high affinity to GPC3 for hepatocellular carcinoma diagnosis","volume":"7","author":"Zhang","year":"2019","journal-title":"Biomater. Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110301_bb0480","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/acs.bioconjchem.6b00030","article-title":"Novel Glypican-3-binding peptide for in vivo hepatocellular carcinoma fluorescent imaging","volume":"27","author":"Zhu","year":"2016","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110301_bb0485","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrc2069","article-title":"G-protein-coupled receptors and cancer","volume":"7","author":"Dorsam","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110301_bb0490","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/acs.molpharmaceut.5b00970","article-title":"Metabolically stabilized 68Ga-NOTA-Bombesin for PET imaging of prostate Cancer and influence of protease inhibitor phosphoramidon","volume":"13","author":"Richter","year":"2016","journal-title":"Mol. Pharm."},{"issue":"30","key":"10.1016\/j.bioorg.2026.110301_bb0495","doi-asserted-by":"crossref","first-page":"11429","DOI":"10.1021\/acs.analchem.3c01765","article-title":"Novel GRPR-targeting peptide for pancreatic Cancer molecular imaging in orthotopic and liver metastasis mouse models","volume":"95","author":"Tu","year":"2023","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bioorg.2026.110301_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105585","article-title":"Discovery of EGFR-targeted environment-sensitive fluorescent probes for cell imaging and efficient tumor detection","volume":"121","author":"Wang","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110301_bb0505","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1021\/acs.analchem.8b04633","article-title":"Discovery of nonpeptide, reversible HER1\/HER2 dual-targeting small-molecule inhibitors as near-infrared fluorescent probes for efficient tumor detection, diagnostic imaging, and drug screening","volume":"91","author":"Liu","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bioorg.2026.110301_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2022.114503","article-title":"Based on lapatinib innovative near-infrared fluorescent probes targeting HER1\/HER2 for in vivo tumors imaging","volume":"214","author":"Li","year":"2022","journal-title":"Biosens. Bioelectron."},{"issue":"29","key":"10.1016\/j.bioorg.2026.110301_bb0515","doi-asserted-by":"crossref","first-page":"24462","DOI":"10.1021\/acsami.7b05617","article-title":"EGFR\/EGFRvIII dual-targeting peptide-mediated drug delivery for enhanced glioma therapy","volume":"9","author":"Mao","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110301_bb0520","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1021\/acs.jmedchem.0c01371","article-title":"Structure-based identification of potent lysine-specific demethylase 1 inhibitor peptides and temporary cyclization to enhance proteolytic stability and cell growth-inhibitory activity","volume":"64","author":"Kitagawa","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110301_bb0525","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jconrel.2018.07.001","article-title":"PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy","volume":"285","author":"Osman","year":"2018","journal-title":"J. Control. Release"},{"issue":"8015","key":"10.1016\/j.bioorg.2026.110301_bb0530","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","article-title":"Covalent targeted radioligands potentiate radionuclide therapy","volume":"630","author":"Cui","year":"2024","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110301_bb0535","doi-asserted-by":"crossref","DOI":"10.1002\/agt2.533","article-title":"From small to large\u2014the application of in situ polymerization within tumor cells","volume":"5","author":"Jia","year":"2024","journal-title":"Aggregate"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110301_bb0540","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nchem.480","article-title":"A biocompatible condensation reaction for controlled assembly of nanostructures in living cells","volume":"2","author":"Liang","year":"2010","journal-title":"Nat. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110301_bb0545","doi-asserted-by":"crossref","first-page":"2106885","DOI":"10.1002\/adma.202106885","article-title":"Enzyme-mediated intracellular polymerization of AIEgens for light-up tumor localization and theranostics","volume":"34","author":"Qi","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.bioorg.2026.110301_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114102","article-title":"Enhanced tumor retention and therapeutic potency in radionuclide therapy using GSH-induced self-assembling peptides","volume":"386","author":"Song","year":"2025","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110301_bb0555","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acscentsci.3c00288","article-title":"Covalent proteins as targeted radionuclide therapies enhance antitumor effects","volume":"9","author":"Klauser","year":"2023","journal-title":"ACS Cent. Sci."},{"issue":"23","key":"10.1016\/j.bioorg.2026.110301_bb0560","doi-asserted-by":"crossref","first-page":"19687","DOI":"10.1021\/jacs.5c02212","article-title":"Chemically engineered affinity protein drugs for covalent targeted Cancer therapy","volume":"147","author":"Xia","year":"2025","journal-title":"J. Am. Chem. Soc."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:56:13Z","timestamp":1791406573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826008370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":112,"alternative-id":["S0045206826008370"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110301","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From tumor imaging probes to boron neutron capture therapy: a strategy for designing targeted boron carriers for pancreatic Cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110301"}}